MARKET

REVB

REVB

Rvltn Bioscnc
NASDAQ
6.65
-1.95
-22.65%
Pre Market: 6.00 -0.65 -9.80% 09:09 02/08 EST
OPEN
9.55
PREV CLOSE
8.60
HIGH
10.68
LOW
6.48
VOLUME
3.49K
TURNOVER
--
52 WEEK HIGH
100.80
52 WEEK LOW
5.91
MARKET CAP
4.47M
P/E (TTM)
-11.4947
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 23h ago
Revelation Biosciences Reveals Encouraging Preclinical Data From Its Lead Fibrosis Candidate
Benzinga · 1d ago
BRIEF-Revelation Bio Announces Preclinical Biomarker Data Supporting Activity Of REVTx-300
Reuters · 1d ago
Revelation Biosciences Announces Preclinical Biomarker Data Supporting Activity Of REVTx-300
Benzinga · 1d ago
Revelation Biosciences Announces 1-For-35 Reverse Stock Split Effective February 1, 2023 And Results Of Special Meeting Of Stockholders; At The Meeting, The Stockholders Also Approved An Increase In The Authorized Common Stock To 500M Shares
Benzinga · 01/31 17:02
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/24 21:31
Why LogicMark Shares Are Trading Lower By Around 25%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/24 13:04
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 01/17 13:06
More
About REVB
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immunologic therapeutics and diagnostics. Its therapeutic product candidates are based on its therapeutic platform and consist of REVTx-100, which is being developed for the prevention or treatment of infections, including those resulting from surgery, severe burns and antibiotic resistance; REVTx-200, which is being developed as intranasal therapy that focuses to be administered with a commercially available intramuscular (IM) vaccine; REVTx-300, which is being developed as a therapy for the treatment of chronic organ disease, including CKD and NASH; and REVTx-99b, which is being developed for the treatment of food allergies. The Company's diagnostic, REVDx-501 (REVIDTM Rapid Test Kit), is being developed as a rapid point of care or at home diagnostic product that can potentially be used to detect various respiratory viral infections.

Webull offers kinds of Revelation Biosciences Inc stock information, including NASDAQ:REVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REVB stock methods without spending real money on the virtual paper trading platform.